Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Effect Of Praziquantel In Liposomes On Schistosoma Mansoni Eggs At Different Development Stages [efeito Do Praziquantel Incorporado A Lipossomas Nos Diferentes Estágios De Desenvolvimento Dos Ovos De Schistosoma Mansoni]
Author: Frezza T.F.
Madi R.R.
Banin T.M.
Pinto M.C.
Souza A.L.R.
Gremiao M.P.D.
Allegretti S.M.
Abstract: Mansonian schistosomiasis is caused by an intravascular digenetic trematode Schistosoma mansoni. Praziquantel (PZQ) and oxamniquine (OXA) are the drugs of choice for the treatment of this disease. However, both drugs are subject to some limitations in their action and cases of tolerance and resistance have been reported. Moreover, tolerance and resistance cases have been reported. For this reason, there is an urgent need for research on new alternatives aimed at improving the action of existing drugs, such as the incorporation of these drugs into liposomes. In this study, the efficiency of action of liposome- encapsulated praziquantel (lip.PZQ) on oviposition by S. mansoni, strain BH, was assessed in Mus musculus mices (SPF Swiss mice). Four PZQ and lip.PZQ doses (47; 60; 250 e 300mg/kg) were tested. Some mice were treated 30 days post-infection and others after 45 days. The oogram analyses showed that the most effective lip.PZQ treatment was 300mg/kg dose given on the 45th day post infection, which reduced the number of S. mansoni eggs per gram of tissue.
Citation: Revista De Ciencias Farmaceuticas Basica E Aplicada. , v. 28, n. 2, p. 209 - 214, 2007.
Rights: aberto
Date Issue: 2007
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
2-s2.0-41349105746.pdf67.38 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.